title: Fatty acids oxidation and alternative energy sources detected in Taenia crassiceps cysticerci after host treatment with antihelminthic drugs.
abstract: Human cysticercosis caused by Taenia crassiceps is rare however it is considered of zoonotic risk. The treatment of the infected patients was successful when using albendazole or praziquantel. The active forms of albendazole inhibit the glucose uptake and the active forms of praziquantel alter glycogen levels and nutrients absorption. The aim of this study was to analyze the production of organic acids that indicate the oxidation of fatty acids and the use of alternative energy sources from T. crassiceps cysticerci removed from the peritoneal cavity of mice treated with low dosages of albendazole (5.75 and 11.5mg/kg) or praziquantel (3.83 and 7.67 mg/kg). The beta-hydroxibutyrate production was higher by the larval stage cysticerci in all treated groups and the propionate production was higher in final stage cysticerci treated with 11.5mg/kg of albendazole when compared to the control group. The larval stages of cysticerci from the groups treated with 5.75 mg/kg of albendazole and 3.83 mg/kg of praziquantel produced more urea than the initial and final stages which indicate amino acids breakdown. We conclude that it was possible to detect the fatty acid oxidation and amino acids breakdown which indicate the use of alternative energy production sources as the used dosages only cause a partial blockage of the glucose uptake and leads to metabolic alterations in the cysticerci. The metabolic behavior observed after host treatment was different from former descriptions of the in vitro one which indicates great host-parasite interaction.
authors.affiliation: Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Setor Universitário, Goiânia, Goiás CEP 74650-050, Brazil.
authors.forename: Carolina Miguel
authors.initials: CM
authors.lastname: Fraga
authors.forename: Tatiane Luiza
authors.initials: TL
authors.lastname: Costa
authors.forename: José Clecildo Barreto
authors.initials: JC
authors.lastname: Bezerra
authors.forename: Ruy
authors.initials: R
authors.lastname: de Souza Lino Junior
authors.forename: Marina Clare
authors.initials: MC
authors.lastname: Vinaud
mesh_terms: D020155:3-Hydroxybutyric Acid / Q000378:metabolism; D000090:Acetoacetates / Q000378:metabolism; D015766:Albendazole / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000871:Anthelmintics / Q000494:pharmacology / Q000627:therapeutic use*; D003404:Creatinine / Q000378:metabolism; D003551:Cysticercosis / Q000188:drug therapy* / Q000469:parasitology; D003552:Cysticercus / Q000187:drug effects / Q000378:metabolism*; D004734:Energy Metabolism / Q000187:drug effects*; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D010084:Oxidation-Reduction; D011223:Praziquantel / Q000494:pharmacology / Q000627:therapeutic use; D011422:Propionates / Q000378:metabolism; D014508:Urea / Q000378:metabolism
chemical_list: D000090:Acetoacetates; D000871:Anthelmintics; D005227:Fatty Acids; D011422:Propionates; D011223:Praziquantel; D014508:Urea; D003404:Creatinine; D015766:Albendazole; D020155:3-Hydroxybutyric Acid